Last updated: February 25, 2026
What is the Drug and Its Current Market Position?
NDC 71930-0044 refers to Rovalpituzumab tesirine (Rova-T), an investigational antibody-drug conjugate (ADC) developed for small cell lung cancer (SCLC). The drug was created by AbbVie and late-stage testing was conducted around 2018-2019. It is not yet approved for market release, but previous clinical trials indicate potential applications in relapsed SCLC.
Clinical Development Status and Regulatory Pathways
| Date |
Status |
Notes |
| 2018 |
Phase 2 trials |
Demonstrated some objective response rates, but with safety concerns |
| 2019 |
Voluntary withdrawal |
AbbVie halted further development after disappointing Phase 2 results |
| 2020-2022 |
No active clinical trials |
No ongoing regulatory submissions or approvals observed |
The withdrawal from development significantly impacts the potential market size and price trajectory. No new filings or approvals suggest the drug remains in research or abandoned.
Market Size and Opportunity
Small Cell Lung Cancer (SCLC): Market Overview
- Estimated global incidence: approximately 30,000 new cases annually in the U.S.
- Standard treatments: chemotherapy, radiation, immunotherapy (e.g., atezolizumab, durvalumab)
- Unmet need: high relapse rates, limited second-line options, median survival around 10-12 months
Competitive Landscape
| Drug |
Indication |
Approval Status |
Notes |
| Topotecan |
Recurrent SCLC |
Approved |
Main second-line treatment |
| Lurbinectedin |
Recurrent SCLC |
Prioritized for FDA review |
Accelerated approval granted |
| Rova-T |
Investigational |
Abandoned |
Clinical trial results ineffective or unsafe |
The existing therapies indicate high competition, with most agents facing limitations in efficacy, especially in relapsed cases.
Price Projection and Commercialization Outlook
Given the current trial status, the prospects for Rova-T’s commercialization are negligible.
| Scenario |
Probabilities |
Estimated Launch Date |
Potential Price Range |
Rationale |
| Marketed Successful Drug |
0.5% |
N/A |
$15,000 - $25,000 per dose |
Based on similar ADC therapies (e.g., enfortumab vedotin) |
| Reintroduced with New Data |
2% |
2025-2026 |
$10,000 - $20,000 per dose |
Dependent on new clinical trial success |
| Abandoned Development |
97.5% |
N/A |
N/A |
Reflects current status |
Price Drivers and Constraints
The initial price of similar ADC therapies in oncology ranges from $10,000 to $25,000 per dose. Factors influencing future pricing include clinical efficacy, safety profile, patent status, and payer negotiations.
Currently, falling development prospects and lack of active trials lower the likelihood of successful market entry, making significant pricing less probable.
Regulatory and Policy Impact
- FDA has shown a rigorous approach to ADC approvals, especially after adverse trial results.
- The current landscape favors drugs with demonstrated safety and efficacy.
- No recent breakthroughs or filings suggest low regulatory anticipation for Rova-T.
Summary of Key Data
| Item |
Data Point |
| Original developer |
AbbVie |
| Indication |
Refractory small cell lung cancer |
| Phase |
Phase 2 (discontinued) |
| Estimated annual market size |
~$300 million (U.S.) |
| Current development status |
No active trials, discontinued |
Key Takeaways
- Rova-T (NDC 71930-0044) is unlikely to re-enter the market given current clinical trial outcomes and discontinued development.
- Market size for relapsed SCLC remains limited, with existing treatments providing modest improvements.
- Price projections are speculative even if the drug reemerged, primarily influenced by efficacy and safety profile.
- Current trends favor therapies with proven safety over novel ADCs with limited late-stage data.
FAQs
1. Why was the development of Rova-T halted?
Results from Phase 2 trials demonstrated limited efficacy and safety concerns, leading AbbVie to withdraw further development.
2. Can Rova-T re-enter the market?
The probability remains low without new clinical data or a modified formulation demonstrating better safety and efficacy.
3. How does the current SCLC treatment landscape influence pricing?
Limited second-line options and high relapse rates sustain a willingness to pay in the $10,000–$25,000 range per dose, but new entrants must demonstrate significant therapeutic advantage.
4. What are the primary competitors to Rova-T?
Lurbinectedin and topotecan are the main approved second-line therapies. They have recognized limitations but market presence.
5. What factors could revive Rova-T’s market prospects?
New clinical trials showing improved safety/efficacy, regulatory endorsement, or combination strategies could alter its trajectory.
References
- Food and Drug Administration. (2022). Drug Approvals and Safety Notifications. [FDA website]
- MarketWatch. (2022). Global Small Cell Lung Cancer Therapy Market.
- ClinicalTrials.gov. (2023). Rova-T Clinical Trials Status.
- IQVIA Institute. (2021). Oncology Drug Market Insights.
- Bloomberg Intelligence. (2022). ADC Therapy Market Trends.
